HQY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Healthequity Inc (HQY) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong financial performance, positive long-term growth prospects in the health savings account market, and favorable analyst ratings, despite some short-term technical overbought signals. The lack of recent negative news and stable insider trading trends further support this conclusion.
The MACD is positive and expanding, indicating bullish momentum. RSI is at 83.072, signaling overbought conditions, which may suggest a short-term pullback. Moving averages are converging, showing potential price consolidation. Key resistance levels are at 83.602 and 85.738, with support at 80.145 and 76.688.
Strong Q4 financial performance with revenue up 7.30% YoY, net income up 88.66% YoY, and EPS up 93.33% YoY.
Analysts maintain positive ratings with raised fiscal 2027 guidance and optimism about HSA market expansion.
Strategic initiatives leveraging AI and Affordable Care Act opportunities.
Favorable long-term growth prospects in the health savings account market.
Hedge funds are selling, with a 213.73% increase in selling activity last quarter.
Overbought technical indicators (RSI above
suggest potential short-term pullback.
Concerns about AI disruption in the health savings account market, though analysts downplay this risk.
In Q4 2026, revenue increased by 7.30% YoY to $334.6M, net income surged by 88.66% YoY to $49.74M, EPS grew by 93.33% YoY to $0.58, and gross margin improved by 15.70% to 60.13%. These results indicate strong growth and operational efficiency.
Analysts are generally positive on HQY, with multiple firms maintaining Buy or Outperform ratings. Price targets range from $85 (BMO Capital) to $128 (Deutsche Bank). Analysts highlight strong HSA growth, fiscal 2027 guidance raises, and strategic initiatives, but some have lowered price targets due to valuation compression and AI concerns.
